A selection of 76 nitroheterocycles and related compounds from our in-house compound library was screened in vitro against the parasite Trypanosoma brucei rhodesiense, causative agent of human African trypanosomiasis (HAT). The unspecific cytotoxicity of the compounds was also evaluated against rat myoblast L6-cells to measure the selectivity of the compounds towards the parasite. This screening revealed some preliminary structure-activity relationships (SAR) among the series, and six hit compounds showing interesting activity (IC 50 ≤ 10 µM) and fair selectivity (SI > 17).
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a neglected tropical disease (NTD) endemic in sub-Saharan Africa. The causative agents are the protozoan parasites Trypanosoma brucei rhodesiense and T. b. gambiense which provoke acute and chronic forms of the disease, respectively. The parasites are transmitted by the bite of infected tsetse flies. In absence of treatment, the parasites present in the blood and lymph during early stage HAT invade the central nervous system (CNS) provoking the fatal meningoencephalitic (late) stage of the disease. 1, 2 The NTD status of sleeping sickness is highlighted by the fact that 3 out of the 4 drugs approved for its treatment (i.e., pentamidine, melarsoprol, suramin) were discovered more that 60 years ago. The other drug, eflornithine, was approved in 1990 for the treatment of late-stage T. b. gambiense infection. Other authors have reviewed the shortcomings of those drugs especially regarding toxicity, lack of oral bioavailability or lack of efficiency. 3 Apart from the recent inclusion of the nifurtimox-eflornithine combination therapy (NECT) 19, 20 Besides, it should be kept in mind that the nitroheterocycles benznidazole and nifurtimox ( Fig. 1 ) are currently the only drugs available for the treatment of American trypanosomiasis which emphasizes the importance of this class of chemical structures as antiprotozoal agents.
We report here the in vitro screening against T. b. rhodesiense (strain STIB900) of a selection of 76 nitro-derivatives of nitrogenated heterocycles (e.g., nitrocinnolines, nitroindoles, nitroindazoles and nitroquinoxalinones) and related compounds 13, 19, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 31 using the Alamar blue growth inhibition assay. 32 Their cytotoxicity against mammalian L6-cells was also determined in vitro. This allowed the calculation of a selectivity index Compounds from the hydrazide series (Table 1) [insert Table 1 here] 5-Nitroindazolols derivatives with free OH group (Table 2) [insert Table 2 here]
Among indazolinone derivatives (Table 3) [insert Table 3 here]
The quinoxalin-2-one scaffold gave the best antitrypanosomal compounds with 6 The bisnitroindazole derivatives were poorly active against T. brucei (Table 5 ). The sole compound with interesting activity was the urea 76 which was one of the best hits of this study with IC 50 = 7.1 µM and SI > 23.6.
[insert Tables 4 and 5 here]
The discovery of fexinidazole as a potential clinical candidate for the oral treatment of both stages of sleeping sickness has led, in the last years, to a renewed interest in nitroheterocyclic compounds as possible antitrypanosomal agents. In this study, we have taken advantage of our compound library, historically rich in nitroheterocyclic compounds, and selected 76 molecules from different groups to be tested against T.
brucei (i.e., nitrobenzohydrazide, indazolol, indazolinone, quinoxalin-2-one, bisindazolols, etc.). From the data collected in this study, the SAR for anti-T. brucei activity is limited even though a few significant trends could be found for the quinoxalin-2-one and indazole series. In particular, the bulk around the N1-position of the molecule seems to be rather restricted. Thus, a small methyl substituent is allowed Interestingly, several of the hits identified in this screening are also lead compounds against T. cruzi or T. vaginalis. On the one hand, 58 showed in vitro activity against epimastigotes and intracellular amastigotes of T. cruzi, as well as in vivo suppressive activity by oral route in a murine model of acute T. cruzi infection. 11 In the same study, Vega et al. showed that 65 was active but more cytotoxic that 58. Hence, despite the moderate selectivity for T. brucei over rat L6-cells (21.6-fold) found in our screening, 58 seems to have adequate physicochemical properties for oral bioavailability and may well be an interesting lead compound worth investigating as anti-T. brucei agent. On the other hand, 34 was reported to be very active against T. vaginalis whilst its activity against T. cruzi was moderate. 13 However, the 2-(2-piperidinoethoxy)ethyl analogue 35
showed similar in vitro anti-T. cruzi efficacy with reduced cytotoxicity compared to 10 These data indicate that 35 may also be a good trypanocidal lead for HAT.
At this stage, the target and mode of action of these compounds against African trypanosomes remain unknown. In T. cruzi, the action of this kind of molecules seems to be associated with the production of reduced species of the 5-NO 2 moiety similarly to what happens with benznidazole 8, 9 or nifurtimox. 33 Thus, the antitrypanosomal action of these compounds, like fexinidazole, could possibly involve bioreductive activation by parasite type I nitroreductase leading to reactive intermediates that would provoke cellular damage. glioxal which in turn leads to glyoxal-guanosine adducts. The authors suggest that the trypanocidal activity of benznidazole is the result of DNA damage by these metabolites. 36 However, the nitroheterocycles reported here cannot be metabolized to glioxal by reductive activation. This means that other mechanism of action (or metabolites) may be involved. This hypothesis will need experimental confirmation.
Altogether, the results of our in vitro screening against T. brucei take their importance in the light of the previous data of antiprotozoal activity reported for those compounds and related nitroimidazoles. For instance, the lead compound fexinidazole, which is currently in clinical trials for HAT, has IC 50 values in the range 1.71-2.93 µM against T.
b. rhodesiense STIB900 in the same assay. 5 Even though fexinidazole selectivity (SI > 322) is higher than that of our compounds, some of the hits presented here could be good starting points for an optimization program directed towards the discovery of new antitrypanosomal agents for the treatment of sleeping sickness. This is the case, in particular, of the 7-nitroquinoxalin-2-one 58 and the 5-nitroindazole 35 that have demonstrated low micromolar activity and in vivo bioavailability in mice . c Bibliographic reference related to other antiparasitic activities of the compound. c Bibliographic reference related to other antiparasitic activities of the compound. c Bibliographic reference related to other antiparasitic activities of the compound. c Bibliographic reference related to other antiparasitic activities of the compound.
